BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN)

CAPS Rating: 3 out of 5

The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

Results 1 - 20 of 113 : 1 2 3 4 5 6 Next »

Recs

0
Member Avatar OBChristenson (31.18) Submitted: 9/5/2014 7:22:10 AM : Underperform Start Price: $68.75 BMRN Score: -0.99

This company hasn't made a profit in four years. The higher the revenue the grater the loss. Definitely not on my watch list.

Recs

0
Member Avatar kevday (98.91) Submitted: 8/22/2014 12:31:08 PM : Underperform Start Price: $70.66 BMRN Score: +2.06

ht Jim O'Shaughnessy

Recs

1
Member Avatar d3ming (38.06) Submitted: 1/31/2014 1:29:57 PM : Outperform Start Price: $68.93 BMRN Score: -11.41

zzporte

Recs

1
Member Avatar chris293 (82.55) Submitted: 1/6/2014 11:59:23 AM : Outperform Start Price: $66.95 BMRN Score: -6.05

Diseases will always need cures, and this company is there though I would like to see more positive numbers.

Recs

0
Member Avatar extramild (< 20) Submitted: 11/29/2013 1:58:26 PM : Underperform Start Price: $70.53 BMRN Score: +12.03

If you look at companies cash flow you will see it is bleeding money at an alarming rate. If this was your business you would have had to put you hand in your pocket for 3 of the last four years to keep this business going.

Recs

0
Member Avatar 1russianguy (69.80) Submitted: 10/9/2013 2:17:07 PM : Outperform Start Price: $66.37 BMRN Score: -15.99

As per Cramer's 08/28/2013: Medivation (MDVN_), Seattle Genetics (SGEN_) and BioMarin (BMRN_): A wave of biotech acquisitions could be coming, said Cramer, and these three companies are prime takeover targets.

Recs

0
Member Avatar 1picks (87.35) Submitted: 10/7/2013 11:15:42 AM : Outperform Start Price: $73.31 BMRN Score: -23.28

As per Cramer's 08/28/2013: Medivation (MDVN_), Seattle Genetics (SGEN_) and BioMarin (BMRN_): A wave of biotech acquisitions could be coming, said Cramer, and these three companies are prime takeover targets.

Recs

0
Member Avatar portico2011 (58.18) Submitted: 9/21/2013 9:35:26 PM : Outperform Start Price: $76.75 BMRN Score: -26.80

Buyout candidate

Recs

0
Member Avatar ronda989 (< 20) Submitted: 9/14/2013 12:19:20 PM : Underperform Start Price: $72.54 BMRN Score: +21.12

http://agbeat.com/business-marketing/public-relations/pr-crisis-making-biomarin-refusing-medication-cancer-fighter/

Recs

0
Member Avatar benyboy (< 20) Submitted: 9/3/2013 5:35:24 AM : Outperform Start Price: $66.50 BMRN Score: -16.65

jim cramer

Recs

0
Member Avatar NHWeston102 (57.23) Submitted: 7/12/2013 1:29:47 PM : Outperform Start Price: $60.62 BMRN Score: -5.05

"Orphans" get adopted...first, ONXX; then, PCYC; and then...BMRN gets a home. If yah can't innovate yerself, buy them what do!!!

Recs

1
Member Avatar kenhawk13f (67.42) Submitted: 3/28/2013 9:25:45 AM : Outperform Start Price: $60.44 BMRN Score: -13.29

Since I bought this stock it has gone up 139% and keeps growing.

Recs

1
Member Avatar jaagu (< 20) Submitted: 12/26/2012 10:51:53 PM : Outperform Start Price: $48.02 BMRN Score: +3.22

It has a niche position for research and development in rare ailments.

Recs

0
Member Avatar lewrose (86.86) Submitted: 12/23/2012 1:40:21 PM : Outperform Start Price: $48.92 BMRN Score: +1.44

Tremendous pipeline of orphan drug candidates

Recs

1
Member Avatar GundersonGroup (28.82) Submitted: 11/5/2012 1:18:27 PM : Underperform Start Price: $48.44 BMRN Score: -1.67

The global target market for Morquio syndrome patients with ability to pay for treatment is around 2500 patients. ThinkEquity analyst Kimberly Lee estimates the market potential of GALNS at 575 million annually. This would be $230,000 annually per patient... It goes without saying that Kimberly's math skills are at a preschool level.

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 6/27/2012 8:43:54 PM : Outperform Start Price: $37.68 BMRN Score: +32.79

porto.likedded it.

Recs

0
Member Avatar IBDContrarian (< 20) Submitted: 5/9/2012 11:50:43 AM : Underperform Start Price: $37.14 BMRN Score: -39.62

IBD EPS, RS, SPROE, Acc ratings plus P/E and div yield
MED 7 89 EB NEG

Recs

0
Member Avatar uvedaleman (28.24) Submitted: 12/25/2011 8:20:06 PM : Outperform Start Price: $33.51 BMRN Score: +48.30

Value of omega 3 fatty acids from ocean getting greater recognition. Efficient extraction process

Recs

1
Member Avatar Lcrazylegs84 (< 20) Submitted: 10/1/2011 12:47:29 AM : Outperform Start Price: $31.70 BMRN Score: +40.88

Up Up and away

Recs

2
Member Avatar navyskindoc (< 20) Submitted: 4/26/2010 11:42:36 PM : Outperform Start Price: $23.18 BMRN Score: +132.95

Good pipeline. Filling niches where big pharma isn't interested in going. Solid front office leadership

Results 1 - 20 of 113 : 1 2 3 4 5 6 Next »

Featured Broker Partners


Advertisement